The Global Clinical Trials Fund covers:
- Studies that aim to demonstrate target engagement, Phase I or Phase II clinical trials undertaken to ascertain the potential safety and efficacy of (novel or re-purposed) drug-based interventions in human subjects
- Clinical trials of non-drug based, complex interventions
- Opportunities for research ‘add ons’ to ongoing clinical trials (e.g. validated biomarker add-ons).
Applications are acceptable from applicants based at established research institutions worldwide. Applications are required to include at least a clinician and an academic investigator or a clinical researcher. Small and medium enterprises may co-apply on clinician/academic-led projects. Applicants who are in collaboration with commercial organisations are acceptable, in particular if these add value to the trial – for example, access to expertise, technologies, reagents or funding.
An upper limit of £500,000 is set for each application as the total Alzheimer’s Research UK contribution. Applicants should be aware that they are competing for limited funds. Proposals should represent good value for money and all funding requests should be clearly justified.
Deadline: 13th November 2019.